Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at patientsupport@clearityfoundation.org.

Results

Save Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial	Phase	Eligible Participant	Official Title	Drugs in Trial	Location
NCT02855944	III	Recurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)	ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	View Drugs	California, Colorado, Georgia, Maine, Michigan, Ohio, Texas
Drug(s) in Trial Other Drug Names Main Known Action Rucaparib CO-338, PF 01367338, AG-014699 PARP inhibitor
NCT03398655	III	Platinum resistant ovarian cancer	A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Ofranergene Obadenovec VB-111 Endothelin promoter-apoptotic receptor gene therapy Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02091141	IIa	Advanced solid tumors with PDL-1 AMP, EGFR, BRAF V600, SMO, PTCH, or ALK mutations or MSI-H or high TMB	My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents	View Drugs	Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, Missouri, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Dakota, Tennessee, Texas, Virginia, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Alectinib ALK inhibitor CH5424802, Alecensa, anaplastic lymphoma kinase inhibitor CH5424802, AF802 ALK kinase inhibitor Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Cobimetinib Cotellic, GDC-0973, XL518 MEK1 inhibitor Erlotinib Tarceva EGFR kinase inhibitor Vemurafenib Zelboraf, PLX4032, RO5185426 BRAF kinase inhibitor Vismodegib Hedgehog antagonist GDC-0449, Erivedge, GDC-0449 Smoothened antagonist
NCT02428712	IIa	Advanced solid tumors including those with BRAF mutations	A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced Unresectable Solid Tumors	View Drugs	Arizona, California, Florida, Massachusetts, Michigan, New York, Pennsylvania, Tennessee, Texas, Utah
Drug(s) in Trial Other Drug Names Main Known Action PLX8394 BRAF inhibitor PLX8394 BRAF kinase inhibitor
NCT02558348	IIa	Platinum refractory or persistent ovarian cancer (< 3 prior therapies) with FGFR 1-3 alterations	A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)	View Drugs	Illinois, Utah
Drug(s) in Trial Other Drug Names Main Known Action AL3818 VEGFR and FGFR kinase inhibitor
NCT02584478	IIa	Recurrent ovarian cancer	A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)	View Drugs	California, Florida, Louisiana, Texas
Drug(s) in Trial Other Drug Names Main Known Action Anlotinib AL3818 VEGFR2/3 kinase inhibitor Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02419417	IIa	Platinum resistant or refractory ovarian cancer with BRCA1/2-mutations	A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies	View Drugs	California, Colorado, Oregon, South Carolina
Drug(s) in Trial Other Drug Names Main Known Action BMS-986158 BET inhibitor BMS-986158 BET inhibitor Nivolumab Anti-PD-1 human mab MDX-1106, MDX-1106, ONO-4538, Opdivo, BMS-936558 Blocks PD-L1/2 inhibition of T cells
NCT02658890	IIa	Advanced solid tumors (in expansion)	A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors	View Drugs	Arizona, California, Florida, Georgia, Illinois, Maryland, Michigan, Missouri, New Jersey, New York, Ohio, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action BMS-986205 Inhibits IDO to stimulate immune response Nivolumab Anti-PD-1 human mab MDX-1106, MDX-1106, ONO-4538, Opdivo, BMS-936558 Blocks PD-L1/2 inhibition of T cells
NCT02839707	II/III	Platinum resistant ovarian cancer	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer	View Drugs	Alaska, Arizona, Arkansas, California, Colorado, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Minnesota, Missouri, Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Bevacizumab anti-VEGF monoclonal antibody, Avastin, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain VEGF antagonist Liposomal doxorubicin Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride Topoisomerase II inhibitor
NCT01325441	II	Platinum resistant or refractory ovarian cancer (< 4 prior cytotoxic therapies)	A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies	View Drugs	Indiana, Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Napabucasin BBI608, cancer stemness inhibitor BBI608 STAT3 and cancer stemness inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02554812	II	Advanced solid tumors (in ovarian expansion)	A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies	View Drugs	California, Connecticut, District of Columbia, Florida, Iowa, Massachusetts, Michigan, New York, North Carolina, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action Avelumab MSB0010718C, Anti-PD-L1, Anti programmed death ligand 1 monoclonal antibody, Bavencio Blocks PD-L1 inhibition of T cells PD-0360324 anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324 CSF1R antagonist and tumor-associated macrophage inhibitor PF-04518600 anti-OX40 antibody PF-04518600 Stimulates OX40 to increase T cell activation and immune response
NCT02832167	II	Advanced solid tumors	An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies	View Drugs	Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action Nivolumab Anti-PD-1 human mab MDX-1106, MDX-1106, ONO-4538, Opdivo, BMS-936558 Blocks PD-L1/2 inhibition of T cells
NCT01851369	II	Advanced solid tumors and granulosa cell ovarian cancer (in expansion)	A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action methoxyamine TRC102 Base excision repair inhibitor Temozolomide Temodal, Temodar, Methazolastone DNA damaging agent
NCT02889900	II	Platinum resistant ovarian cancer without germline BRCA1/2 mutations (at least 3 prior therapies)	A Single Arm, Open-label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women With Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation	View Drugs	Alabama, Alaska, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Kansas, Louisiana, Maryland, Massachusetts, Michigan, Montana, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action Cediranib AZD2171, Cediranib maleate, Recentin VEGFR1-3 kinase inhibitor Olaparib Lynparza, AZD2281 PARP inhibitor
NCT01690468	II	Platinum resistant or persistent ovarian cancer	A Phase IA/IB Trial of PTX-200 and Carboplatin in Patients With Platinum-Resistant Recurrent Ovarian Cancer	View Drugs	Florida
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Triciribine TCN-PM, PTX-200, tricycloside phosphate, tricyclic nucleoside, triciribine phosphate, API-2, TCN, NSC 154020, Akt/PKB Signaling Inhibitor-2, Inhibitor V, VD-0002 AKT phosphorylation inhibitor
NCT02853318	II	Recurrent ovarian cancer	A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	View Drugs	New York
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab anti-VEGF monoclonal antibody, Avastin, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain VEGF antagonist Cyclophosphamide Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan DNA damaging agent Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT02873975	II	Advanced solid tumors with MYC or CCNE1 amplification, Rb loss, or FBXW7, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHEK2, Fanconi anemia pathway mutations	A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Prexasertib checkpoint kinase 1 inhibitor LY2606368, LY2606368 Chk1/2 inhibitor
NCT02901899	II	Platinum resistant ovarian cancer	An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer	View Drugs	Illinois
Drug(s) in Trial Other Drug Names Main Known Action Guadecitabine DNA methyltransferase inhibitor SGI-110, SGI-110 DNA methylation inhibitor Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT02432378	II	Platinum sensitive ovarian cancer with first recurrence in peritoneal cavity	A Phase 1-2 Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 Vaccines	View Drugs	Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Alpha-DC1 vaccine Anti-tumor immune response Celecoxib Celebrex Cisplatin CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin DNA damaging agent
NCT02364713	II	Platinum resistant, refractory or persistent ovarian cancer (disease outside the peritoneal cavity)	A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer	View Drugs	Minnesota
Drug(s) in Trial Other Drug Names Main Known Action MV-NIS oncolytic measles virus encoding thyroidal sodium iodide symporter Induces immune response and tumor cell lysis
NCT02948101	II	Platinum resistant or refractory ovarian cancer	Pilot Study of the Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Cyclophosphamide Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan DNA damaging agent PD-0360324 anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324 CSF1R antagonist and tumor-associated macrophage inhibitor
NCT02098343	II	Platinum sensitive p53+ high grade serous ovarian cancer (< 3 prior platinum therapies)	PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	View Drugs	California, Illinois, Massachusetts, Michigan, Oregon, Pennsylvania, Tennessee, Texas, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action APR-246 PRIMA-1 analogue APR-246, p53 activator APR-246, PRIMA-1MET p53 activator Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Liposomal doxorubicin Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride Topoisomerase II inhibitor
NCT02608268	II	Advanced solid tumors (in expansion)	Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies	View Drugs	Maryland, Massachusetts, Texas
Drug(s) in Trial Other Drug Names Main Known Action MBG453 Anti-TIM-3 Monoclonal Antibody MBG453, Anti-TIM3 Checkpoint Inhibitor MBG453 Blocks TIM-3 inhibition of T cells PDR001 anti-PD-1 monoclonal antibody PDR001 Blocks PD-L1/2 inhibition of T cells
NCT02834013	II	Advanced ovarian germ cell, mucinous, squamous cell, or adenocarcinoma	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	View Drugs	Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Yervoy, MDX-010, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody Blocks CTLA-4 inhibition of T cells Nivolumab Anti-PD-1 human mab MDX-1106, MDX-1106, ONO-4538, Opdivo, BMS-936558 Blocks PD-L1/2 inhibition of T cells
NCT02900560	II	Platinum resistant or refractory ovarian cancer (< 3 prior therapies for platinum resistant disease)	Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	View Drugs	California, Minnesota, Ohio
Drug(s) in Trial Other Drug Names Main Known Action Oral Azacitidine CC-486 DNA methylation inhibitor Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT02843165	II	Advanced solid tumors with lesion treatable with radiotherapy	Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Ipilimumab Yervoy, MDX-010, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody Blocks CTLA-4 inhibition of T cells Nivolumab Anti-PD-1 human mab MDX-1106, MDX-1106, ONO-4538, Opdivo, BMS-936558 Blocks PD-L1/2 inhibition of T cells Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT01697527	II	Advanced NY-ESO-1+ solid tumors	Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Malignancies	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action Cyclophosphamide Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan DNA damaging agent Fludarabine Fludara Oral, 2-F-ara-AMP, Beneflur DNA synthesis inhibitor NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL anti-NY-ESO-1 TCR gene-engineered lymphocytes Immune response against cancer expressing NY-ESO-1 NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine Immune response against cancer expressing NY-ESO-1
NCT02675829	II	Advanced solid tumors with HER2 amplification	A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers	View Drugs	New York
Drug(s) in Trial Other Drug Names Main Known Action Trastuzumab emtansine ado trastuzumab emtansine, Kadcyla, T-DM1, trastuzumab-DM1, trastuzumab-MCC-DM1, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1 immunoconjugate ADC: anti-HER2 + microtubule destabilizer (DM1)
NCT02568267	II	Advanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangements	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	View Drugs	Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New Hampshire, New York, North Carolina, Ohio, Oklahoma, Oregon, Texas, Utah, Virginia, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Entrectinib RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101 ALK, TRK, ROS1 kinase inhibitor
NCT02595892	II	Platinum resistant high grade serous ovarian cancer (only 1 prior therapy for platinum resistant disease)	Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer	View Drugs	Arizona, California, Florida, Massachusetts, Michigan, Minnesota, Pennsylvania, Tennessee, Texas, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Berzosertib VX-970, M6620, VE-822, ATR kinase inhibitor VX-970 ATR kinase inhibitor Gemcitabine Gemzar Ribonucleotide reductase and DNA synthesis inhibitor
NCT02608684	II	Platinum resistant ovarian cancer	A Phase II Study of Pembrolizumab With Cisplatin and Gemcitabine Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action Cisplatin CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin DNA damaging agent Gemcitabine Gemzar Ribonucleotide reductase and DNA synthesis inhibitor Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT02693535	II	Advanced solid tumors with defined molecular alterations (VEGFR, Bcr-abl, SRC, LYN, LCK, ALK, ROS1, MET,CDKN2A/p16, CDK4, CDK6, CSF1R, PDGFR, mTOR, TSC, ERBB2, BRAFV600E, Bcr-abl, SRC, KIT, PDGFRB, RAF-1,BRAF, EPHA2, FYN, LCK, YES1, RET, BRCA1/BRCA2, ATM, POLD, POLE, highTMB)	Targeted Agent and Profiling Utilization Registry (TAPUR) Study	View Drugs	Alabama, Arizona, California, Florida, Georgia, Illinois, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action Axitinib Inlyta, AG-013736 Multi-targeted RTK inhibitor Bosutinib Bosulif, SKI-606 Abl and src family kinase inhibitor Cetuximab Erbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225 EGFR antagonist Cobimetinib Cotellic, GDC-0973, XL518 MEK1 inhibitor Crizotinib c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori c-Met and ALK kinase inhibitor Dasatinib BMS-354825, Sprycel SRC and bcr-abl kinase inhibitor Ipilimumab Yervoy, MDX-010, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody Blocks CTLA-4 inhibition of T cells Nivolumab Anti-PD-1 human mab MDX-1106, MDX-1106, ONO-4538, Opdivo, BMS-936558 Blocks PD-L1/2 inhibition of T cells Olaparib Lynparza, AZD2281 PARP inhibitor Palbociclib Ibrance, PD0332991, PD-0332991 CDK4/6 inhibitor Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells Pertuzumab Perjeta, monoclonal antibody 2C4, rhuMAb2C4 HER2 dimerization inhibitor Regorafanib BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga Multi-targeted RTK inhibitor Sunitinib Sunitinib malate, Sutent VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit Temsirolimus CCI-779, Torisel mTOR inhibitor Trastuzumab Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody HER2 antagonist Vemurafenib Zelboraf, PLX4032, RO5185426 BRAF kinase inhibitor
NCT02465060	II	Advanced solid tumors with alterations in AKT1, BRAF, BRCA1/2, CCND1-3 AMP, CDK4/6 AMP, DDR2, EGFR, ERBB2, ERBB2 AMP, FGFR1-3, GNAQ, GNA11, MET AMP, NF1/2, NRAS, NTRK1-3, PIK3CA, PTCH1, PTEN, SMO, TSC1/2 or dMMR	Molecular Analysis for Therapy Choice (MATCH)	View Drugs	Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib AZD1775, MK1775, WEE1 inhibitor AZD1775 WEE1 inhibitor Afatinib BIBW 2992 MA2, Gilotrif, Afatinib dimaleate EGFR, HER2, HER4 kinase inhibitor AZD4547 FGFR inhibitor AZD4547 FGFR1-3 inhibitor AZD5363 Akt inhibitor AZD5363 pan-AKT inhibitor Binimetinib ARRY-438162, ARRY-162, MEK inhibitor MEK162, MEK162 MEK inhibitor Crizotinib c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori c-Met and ALK kinase inhibitor Dabrafenib Tafinlar, GSK2118436, BRAF inhibitor GSK2118436, GSK-2118436A BRAF kinase inhibitor Dasatinib BMS-354825, Sprycel SRC and bcr-abl kinase inhibitor Defactinib PF-04554878, PF-04554878, VS-6063 FAK inhibitor GSK2636771 PI3K-beta Inhibitor GSK2636771 PI3K beta inhibitor LOXO-101 Trk inhibitor LOXO-101 Pan-Trk kinase inhibitor Nivolumab Anti-PD-1 human mab MDX-1106, MDX-1106, ONO-4538, Opdivo, BMS-936558 Blocks PD-L1/2 inhibition of T cells Osimertinib Tagrisso, AZD9291, EGFR inhibitor AZD9291, Mereletinib EGFR kinase inhibitor Palbociclib Ibrance, PD0332991, PD-0332991 CDK4/6 inhibitor Sapanisertib TAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128 TORC1/2 kinase inhibitor Taselisib GDC-0032 PI3K alpha inhibitor Trametinib Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212 MEK1/2 inhibitor Trastuzumab Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody HER2 antagonist Trastuzumab emtansine ado trastuzumab emtansine, Kadcyla, T-DM1, trastuzumab-DM1, trastuzumab-MCC-DM1, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1 immunoconjugate ADC: anti-HER2 + microtubule destabilizer (DM1) Vismodegib Hedgehog antagonist GDC-0449, Erivedge, GDC-0449 Smoothened antagonist
NCT02628067	II	Advanced solid tumors with high MSI	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	View Drugs	California, Colorado, Florida, Maryland, Massachusetts, Minnesota, New Jersey, New Mexico, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT02576444	II	Advanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutations	A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors	View Drugs	Connecticut, Massachusetts, Ohio, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib AZD1775, MK1775, WEE1 inhibitor AZD1775 WEE1 inhibitor AZD5363 Akt inhibitor AZD5363 pan-AKT inhibitor AZD6738 ATR kinase inhibitor Olaparib Lynparza, AZD2281 PARP inhibitor
NCT02325739	II	Advanced solid tumors (in expansion)	A Phase I/II, Multicenter, Open-label Study of Oral FGF401 in Adult Patients With Hepatocellular Carcinoma or Solid Malignancies Characterized by Positive FGFR4 and KLB Expression	View Drugs	California, Massachusetts, Texas
Drug(s) in Trial Other Drug Names Main Known Action FGF401 FGFR4 inhibitor FGF401 FGFR4 inhibitor
NCT02571725	II	Recurrent ovarian cancer with germline BRCA1/2 mutations	A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer	View Drugs	Florida, New Mexico, Ohio, Virginia
Drug(s) in Trial Other Drug Names Main Known Action Olaparib Lynparza, AZD2281 PARP inhibitor Tremelimumab anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab Blocks CTLA-4 inhibition of T cells
NCT02485990	II	Platinum resistant, refractory, partially sensitive or persistent ovarian cancer (1 prior platinum-taxane)	An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action Olaparib Lynparza, AZD2281 PARP inhibitor Tremelimumab anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab Blocks CTLA-4 inhibition of T cells
NCT02203513	II	Recurrent high grade serous or endometrioid or germline BRCA1/2-mutated ovarian cancer	A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action Prexasertib checkpoint kinase 1 inhibitor LY2606368, LY2606368 Chk1/2 inhibitor
NCT02079740	II	Advanced solid tumors with KRAS or NRAS mutations (in expansion)	An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Navitoclax Bcl-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT-263 Bcl-2, Bcl-XL, and Bcl-w inhibitor Trametinib Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212 MEK1/2 inhibitor
NCT02201212	II	Advanced solid tumors with TSC1/2 mutations	A Phase II Trial of Everolimus for Cancer Patients With Inactivating Mutations in TSC1 or TSC2 or Activating MTOR Mutations	View Drugs	Massachusetts, New York
Drug(s) in Trial Other Drug Names Main Known Action Everolimus Afinitor, Certican, RAD001, Zortress mTOR inhibitor
NCT02484404	II	Platinum resistant or refractory ovarian cancer ( > 2 prior platinum therapies)	Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action Cediranib AZD2171, Cediranib maleate, Recentin VEGFR1-3 kinase inhibitor Durvalumab MEDI4736, Anti-B7H1 Monoclonal Antibody MEDI4736, Imfinzi Blocks PD-L1 inhibition of T cells Olaparib Lynparza, AZD2281 PARP inhibitor
NCT01037790	II	Advanced solid tumors with CCND1/2 AMP, CDK4/6 MUT, or other G1/S alterations	Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	View Drugs	Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Palbociclib Ibrance, PD0332991, PD-0332991 CDK4/6 inhibitor
NCT01953926	II	Advanced solid tumors with activating HER2 mutations	An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.	View Drugs	California, Florida, Illinois, Louisiana, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Neratinib HKI-272, PD272 EGFR, HER2, HER4 kinase inhibitor
NCT02253992	II	Advanced solid tumors (in expansion)	A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma	View Drugs	California, Florida, Illinois, Maryland, Massachusetts, New York, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action Nivolumab Anti-PD-1 human mab MDX-1106, MDX-1106, ONO-4538, Opdivo, BMS-936558 Blocks PD-L1/2 inhibition of T cells Urelumab BMS-663513, anti-CD137 monoclonal antibody, anti-4-1BB monoclonal antibody Stimulates 4-1BB (CD137) to increase T cells and immune response
NCT02312245	II	Platinum resistant or refractory ovarian cancer	Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers	View Drugs	Arizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action Gemcitabine Gemzar Ribonucleotide reductase and DNA synthesis inhibitor Liposomal doxorubicin Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride Topoisomerase II inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Topotecan Hycamptamine, Hycamtin, TOPO Topoisomerase I inhibitor
NCT02318277	II	Advanced solid tumors (in expansion)	A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)	View Drugs	California, Colorado, Florida, Illinois, Kentucky, North Carolina, Texas
Drug(s) in Trial Other Drug Names Main Known Action Durvalumab MEDI4736, Anti-B7H1 Monoclonal Antibody MEDI4736, Imfinzi Blocks PD-L1 inhibition of T cells Epacadostat IDO1 Inhibitor INCB024360, INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, 3-dioxygenase Inhibitor INCB024360 Inhibits IDO to stimulate immune response
NCT01974765	II	Platinum resistant, refractory, partially sensitive or persistent AR+ ovarian cancer or treated with at least 2 prior platinum therapies	A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies	View Drugs	New Jersey, New York
Drug(s) in Trial Other Drug Names Main Known Action Enzalutamide Xtandi, MDV3100 AR antagonist
NCT02272998	II	Advanced Solid Tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterations	Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)	View Drugs	Michigan, Ohio
Drug(s) in Trial Other Drug Names Main Known Action Ponatinib multitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534 Multi-targeted kinase inhibitor
NCT02034110	II	Advanced solid tumors with BRAF V600E mutations	A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib	View Drugs	Arkansas, California, Maryland, Massachusetts, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action Dabrafenib Tafinlar, GSK2118436, BRAF inhibitor GSK2118436, GSK-2118436A BRAF kinase inhibitor Trametinib Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212 MEK1/2 inhibitor
NCT03414047	II	Platinum resistant or refractory high grade serous ovarian cancer	A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer	View Drugs	Arizona, California, Florida, Massachusetts, Missouri, New Hampshire, Oklahoma, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington
Drug(s) in Trial Other Drug Names Main Known Action Prexasertib checkpoint kinase 1 inhibitor LY2606368, LY2606368 Chk1/2 inhibitor
NCT03365791	II	Advanced solid tumors	Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.	View Drugs	California, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Maryland, Montana, Nebraska, Nevada, North Carolina, Oregon, Pennsylvania, Texas, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action LAG525 anti-LAG-3 monoclonal antibody LAG525 Blocks LAG-3 inhibition of T cells PDR001 anti-PD-1 monoclonal antibody PDR001 Blocks PD-L1/2 inhibition of T cells
NCT03428802	II	Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations	A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability	View Drugs	New Jersey
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT01876511	II	Advanced solid tumors with positive MSI or tumors with negative MSI and high TMB	Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors	View Drugs	California, Maryland, Ohio, Oregon, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT03462342	II	Recurrent ovarian cancer	Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer	View Drugs	Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action AZD6738 ATR kinase inhibitor Olaparib Lynparza, AZD2281 PARP inhibitor
NCT03310879	II	Advanced solid tumors with CCND1, CCND2, or CCND3 alterations or CDK4/6 amplifications	A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Abemaciclib Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio CDK4/6 inhibitor
NCT03348631	II	Recurrent or persistent endometrioid/clear cell ovarian cancer	A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent Endometrioid/Clear Cell Carcinoma of the Ovary or Peritoneum, and Recurrent Low Grade Endometrioid Endometrial Adenocarcinoma	View Drugs	Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Tazemetostat histone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438 EZH2 histone methyltransferase inhibitor
NCT03355976	II	Recurrent clear cell ovarian cancer	BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas	View Drugs	Rhode Island
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Yervoy, MDX-010, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody Blocks CTLA-4 inhibition of T cells Nivolumab Anti-PD-1 human mab MDX-1106, MDX-1106, ONO-4538, Opdivo, BMS-936558 Blocks PD-L1/2 inhibition of T cells
NCT03342417	II	Platinum resistant or refractory ovarian cancer	Phase 2 Study of Combination of Nivolumab and Ipilimumab in (1) Neoadjuvant Setting in Previously Untreated Breast Cancer Patients, (2) Platinum-Resistant/Refractory Advanced Ovarian Cancer Patients; and (3) Advanced Gastric Cancer Patients	View Drugs	New York
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Yervoy, MDX-010, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody Blocks CTLA-4 inhibition of T cells Nivolumab Anti-PD-1 human mab MDX-1106, MDX-1106, ONO-4538, Opdivo, BMS-936558 Blocks PD-L1/2 inhibition of T cells
NCT03312114	II	Recurrent or persistent ovarian cancer (tumor amenable to radiation)	Phase II Trial of Concurrent Anti—PD-L1 and SAbR for Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (With Safety lead-in)	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Avelumab MSB0010718C, Anti-PD-L1, Anti programmed death ligand 1 monoclonal antibody, Bavencio Blocks PD-L1 inhibition of T cells
NCT03147976	II	Advanced solid tumors with MET over-expression or mutation	A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Solid Tumors That Overexpress Mesenchymal Epithelial Transition (MET) or Harbor MET Exon 14 Skipping (METex14del) Mutations	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action AMG 337 c-Met kinase inhibitor
NCT03395080	II	Platinum resistant or refractory ovarian cancer	A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer	View Drugs	Alabama, Florida, Massachusetts, Missouri, Oklahoma, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action DKN-01 DKK1-neutralizing monoclonal antibody DKN-01 Dickkopf-1 (DKK1) antagonist
NCT02983799	II	Platinum sensitive recurrent ovarian cancer (> 1 prior therapy)	Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy	View Drugs	Alaska, California, Connecticut, Delaware, Florida, Illinois, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action Olaparib Lynparza, AZD2281 PARP inhibitor
NCT03026062	II	Platinum resistant or refractory ovarian cancer	Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Durvalumab MEDI4736, Anti-B7H1 Monoclonal Antibody MEDI4736, Imfinzi Blocks PD-L1 inhibition of T cells Tremelimumab anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab Blocks CTLA-4 inhibition of T cells
NCT03093155	II	Platinum resistant, refractory or persistent ovarian cancer	A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers	View Drugs	Connecticut, Maryland
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab anti-VEGF monoclonal antibody, Avastin, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain VEGF antagonist Ixabepilone Azaepothilone B, BMS-247550, epothilone B lactam, Epothilone-B, Ixempra Microtubule stabilizer/mitotic inhibitor
NCT02354131	II	Platinum sensitive, recurrent high grade serous or endometrioid ovarian cancer	Part 1: AVANOVA1 - A Phase I Study to Evaluate the Safety and Tolerability of Bevacizumab-niraparib Combination Therapy and Determine the Recommended Phase 2 Dose (RP2D) in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Part 2: AVANOVA2 - A Two-arm, Open-label, Phase II Randomized Study to Evaluate the Efficacy of Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer.	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab anti-VEGF monoclonal antibody, Avastin, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain VEGF antagonist Niraparib MK4827 PARP inhibitor
NCT02920996	II	Advanced solid tumors with NTRK1-3 rearrangements	A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Merestinib c-Met inhibitor LY2801653, LY2801653 Multi-targeted RTK inhibitor
NCT02587598	II	Advanced solid tumors (in expansion)	A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies	View Drugs	Arizona, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Michigan, Nebraska, New York, Oklahoma, Tennessee, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action INCB053914 pan-PIM inhibitor INCB053914 PIM1, 2, 3 inhibitor
NCT03113487	II	Platinum resistant ovarian cancer (<4 prior cytotoxic therapies)	P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action MVA-p53 vaccine Modified Vaccinia Virus Ankara Vaccine Expressing p53, p53MVA, p53MVA vaccine Immune response against p53 tumor antigen Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT03253679	II	Advanced solid tumors with CCNE1 AMP	A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib AZD1775, MK1775, WEE1 inhibitor AZD1775 WEE1 inhibitor
NCT03029611	II	Newly diagnosed stage III-IV ovarian cancer (neo-adjuvant)	A Phase II Study of Concurrent IGFBP-2 Vaccination and Neoadjuvant Chemotherapy to Increase the Rate of Pathologic Complete Response at the Time of Cytoreductive Surgery	View Drugs	Washington
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent IGFBP-2 vaccine pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine Immune response against cancer expressing IGFBP-2 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT03274661	II	Advanced solid tumors	Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency	View Drugs	Florida
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT03146663	II	Platinum resistant high grade serous or endometrioid ovarian cancer (at least 3 prior therapies)	A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer	View Drugs	Arizona, California, Colorado, Florida, Illinois, Minnesota, Missouri, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action NUC-1031 gemcitabine ProTide, Acelarin, gemcitabine-phosphoramidate NUC-1031 Ribonucleotide reductase and DNA synthesis inhibitor
NCT03284385	II	Advanced solid tumors with SETD2 deficiency	A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies	View Drugs	California, District of Columbia, Maryland, Massachusetts, Missouri, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib AZD1775, MK1775, WEE1 inhibitor AZD1775 WEE1 inhibitor
NCT03300843	II	Advanced solid tumors (with resectable tumor)	A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action Peptide loaded dendritic cell vaccine Anti-tumor immune response
NCT03456700	II	Recurrent serous ovarian cancer	Phase II Trial to Evaluate the Efficacy of Auranofin and Sirolimus in Serous Ovarian Cancer Patients With Recurrent Disease	View Drugs	Minnesota
Drug(s) in Trial Other Drug Names Main Known Action Auranofin Ridaura Thioredoxin reductase inhibitor Sirolimus Rapamune, Rapamycin mTOR inhibitor
NCT03386721	II	Advanced solid tumors	An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of RO6874281, an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors	View Drugs	New Jersey
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Gemcitabine Gemzar Ribonucleotide reductase and DNA synthesis inhibitor RO6874281 anti-FAP/interleukin-2 fusion protein RO6874281 Immune response against cancer expressing FAP Vinorelbine Biovelbin, Eunades, Navelbine, Navelbine ditartrate, NVB, Vinorelbine tartrate, VNB, Vinorelbine ditartrate Tubulin polymerization inhibitor
NCT03570619	II	Advanced solid tumors with CDK12 alterations	IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations	View Drugs	Michigan
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Yervoy, MDX-010, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody Blocks CTLA-4 inhibition of T cells Nivolumab Anti-PD-1 human mab MDX-1106, MDX-1106, ONO-4538, Opdivo, BMS-936558 Blocks PD-L1/2 inhibition of T cells
NCT03565991	II	Advanced solid tumors with BRCA1/2 or ATM mutations	A Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant Tumors	View Drugs	New Jersey, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action Avelumab MSB0010718C, Anti-PD-L1, Anti programmed death ligand 1 monoclonal antibody, Bavencio Blocks PD-L1 inhibition of T cells Talazoparib Talazoparib Tosylate, BMN-673, MDV3800 PARP inhibitor
NCT03579316	II	Platinum resistant or refractory ovarian cancer (PD on prior PARP inhibitor)	A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP Inhibition	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib AZD1775, MK1775, WEE1 inhibitor AZD1775 WEE1 inhibitor Olaparib Lynparza, AZD2281 PARP inhibitor
NCT03602586	II	Recurrent or persistent clear cell ovarian cancer	A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary	View Drugs	Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Epacadostat IDO1 Inhibitor INCB024360, INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, 3-dioxygenase Inhibitor INCB024360 Inhibits IDO to stimulate immune response Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT03610490	II	Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma	Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action MDA-TIL autologous tumor-infiltrating lymphocytes MDA-TIL Anti-tumor immune response
NCT02683395	Ib/IIa	Advanced solid tumors	A Phase 1b/2a, Two-Part, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX51107 in Subjects With Advanced Hematological Malignancies and Solid Tumors	View Drugs	New York, Ohio, Pennsylvania, South Carolina, Texas
Drug(s) in Trial Other Drug Names Main Known Action PLX51107 BRD4 inhibitor PLX51107 BRD4 inhibitor
NCT03330405	Ib/II	Platinum sensitive recurrent ovarian cancer	A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors	View Drugs	Arkansas, Massachusetts, Michigan, New York, Ohio, Texas
Drug(s) in Trial Other Drug Names Main Known Action Avelumab MSB0010718C, Anti-PD-L1, Anti programmed death ligand 1 monoclonal antibody, Bavencio Blocks PD-L1 inhibition of T cells Talazoparib Talazoparib Tosylate, BMN-673, MDV3800 PARP inhibitor
NCT02759588	Ib/II	Platinum resistant, refractory or partially sensitive ovarian cancer (with peritoneal disease)	Phase 1b/2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer (VIRO-15)	View Drugs	California, Florida
Drug(s) in Trial Other Drug Names Main Known Action GL-ONC1 light-emitting oncolytic vaccinia virus GL-ONC1 Membrane disrupter
NCT02099058	Ib	Advanced solid tumors (in expansion)	A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors	View Drugs	California, Colorado, Illinois, Massachusetts, Michigan, Missouri, North Carolina, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action ABBV-399 ADC: anti-cMET + cytotoxic molecule Erlotinib Tarceva EGFR kinase inhibitor Nivolumab Anti-PD-1 human mab MDX-1106, MDX-1106, ONO-4538, Opdivo, BMS-936558 Blocks PD-L1/2 inhibition of T cells
NCT02953782	Ib	Advanced solid tumors	A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer	View Drugs	California, Michigan, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action Cetuximab Erbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225 EGFR antagonist Hu5F9-G4 anti-CD47 monoclonal antibody Hu5F9-G4 Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis
NCT02323191	Ib	Advanced solid tumors (inc ovarian expansion)	Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Phase to Evaluate the Safety, Pharmacokinetics, and Activity of RO5509554 (Emactuzumab) and MPDL3280A (Atezolizumab) Administered in Combination in Patients With Advanced Solid Tumors	View Drugs	Connecticut, Massachusetts, New York
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Emactuzumab RG7155, RO5509554 CSF1R antagonist and tumor-associated macrophage inhibitor
NCT02511795	Ib	Advanced solid tumors	A Phase Ib Study of AZD1775 and Olaparib in Patients With Refractory Solid Tumours	View Drugs	Colorado, Florida, New York, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib AZD1775, MK1775, WEE1 inhibitor AZD1775 WEE1 inhibitor Olaparib Lynparza, AZD2281 PARP inhibitor
NCT02751918	Ib	Platinum resistant mesothelin+ ovarian cancer	An Open-label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin 30 mg/m2 Given Every 3 Weeks in Subjects With Mesothelin-expressing Platinum-resistant Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer	View Drugs	California, Colorado, Connecticut, Ohio, Oklahoma, Oregon
Drug(s) in Trial Other Drug Names Main Known Action Anetumab ravtansine Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343, BAY 94-9343 ADC: anti-mesothelin + microtubule destabilizer (DM4) Liposomal doxorubicin Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride Topoisomerase II inhibitor
NCT02785250	Ib	Recurrent ovarian cancer	A Phase 1b Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer	View Drugs	California, Georgia, New York, Oregon, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action Cyclophosphamide Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan DNA damaging agent DPX-Survivac survivin antigen vaccine DPX-Survivac Immune response against cancer expressing survivin Epacadostat IDO1 Inhibitor INCB024360, INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, 3-dioxygenase Inhibitor INCB024360 Inhibits IDO to stimulate immune response
NCT02719691	Ib	Advanced solid tumors	A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibitor, Alisertib) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Triple-negative Breast Cancer (TNBC)	View Drugs	Colorado
Drug(s) in Trial Other Drug Names Main Known Action Alisertib MLN8237 Aurora A kinase inhibitor Sapanisertib TAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128 TORC1/2 kinase inhibitor
NCT02784795	Ib	Advanced solid tumors	A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors	View Drugs	California, Florida, Massachusetts, Michigan, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action Abemaciclib Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio CDK4/6 inhibitor Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Cisplatin CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin DNA damaging agent Gemcitabine Gemzar Ribonucleotide reductase and DNA synthesis inhibitor LY3023414 PI3K/mTOR inhibitor LY3023414 PI3K/mTOR inhibitor LY3039478 Gamma-secretase inhibitor Taladegib LY2940680 Smoothened antagonist
NCT02551185	Ib	Advanced solid tumors	A Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action ACY-241 HDAC inhibitor ACY-241, histone deacetylase inhibitor ACY-241 HDAC inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02606305	Ib	Advanced FRalpha+ ovarian cancer (inc expansion)	A Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer	View Drugs	Massachusetts, Ohio, Oklahoma, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab anti-VEGF monoclonal antibody, Avastin, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain VEGF antagonist Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Mirvetuximab Soravtansine Anti-FOLR1-mab Maytansinoid Conjugate, IMGN853, M9346A-sulfo-SPDB-DM4 ADC: anti-FOLR1 + microtubule destabilizer (DM4) Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT02649673	Ib	Recurrent ovarian cancer (in expansion)	Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies	View Drugs	Florida, Oklahoma, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action LCL161 SMAC mimetic LCL161 SMAC mimetic and IAP antagonist Topotecan Hycamptamine, Hycamtin, TOPO Topoisomerase I inhibitor
NCT03319628	Ib	Platinum resistant ovarian cancer (inc expansion)	A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b	View Drugs	Massachusetts, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action XMT-1536 ADC: anti-NaPi2b + microtubule destabilizer (auristatin)
NCT03318445	Ib	Advanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion)	Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action Irinotecan Campothecin-11, Campto, Camptosar Topoisomerase I inhibitor Rucaparib CO-338, PF 01367338, AG-014699 PARP inhibitor
NCT03307785	Ib	Advanced solid tumors (< 5 prior therapies)	Phase 1b Dose-Finding Study of Niraparib, Niraparib/Bevacizumab, Carboplatin-Paclitaxel, or Carboplatin-Paclitaxel/Bevacizumab in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer	View Drugs	Arizona, California, Florida, Ohio, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab anti-VEGF monoclonal antibody, Avastin, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain VEGF antagonist Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Niraparib MK4827 PARP inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor TSR-042 ANB011, anti-PD-1 monoclonal antibody TSR-042 Blocks PD-L1/2 inhibition of T cells
NCT03168061	Ib	Advanced solid tumors	A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients With Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma	View Drugs	California, Indiana, Missouri, Nevada, New York, North Carolina
Drug(s) in Trial Other Drug Names Main Known Action NC-6300 epirubicin-incorporating micelle, epirubicin-conjugated polymer micelles, nanoparticle epirubicin, micellar nanoparticle-encapsulated epirubicin, K-912 Topoisomerase II inhibitor
NCT02304393	Ib	Advanced solid tumors (in expansion)	An Open-Label, Multicenter, Dose-Escalation Phase IB Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonist) in Combination With Atezolizumab (Anti PD-L1) in Patients With Locally Advanced and/or Metastatic Solid Tumors	View Drugs	Alabama, Arizona, California, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Selicrelumab CD40 agonist monoclonal antibody RO7009789 Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response
NCT02660034	Ib	Platinum sensitive recurrent ovarian cancer (at least 2 prior platinum regimens)	A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors	View Drugs	Arizona, California, Colorado, Florida, Massachusetts, New York, Pennsylvania, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action BGB-290 PARP inhibitor BGB-290 PARP inhibitor BGB-A317 anti-PD-1 monoclonal antibody BGB-A317 Blocks PD-L1/2 inhibition of T cells
NCT03099174	Ib	Advanced solid tumors	An Open Label, Phase Ib Dose-escalation Study Evaluating the Safety and Tolerability of BI 836845 and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive Breast Cancer, Followed by Expansion Cohorts	View Drugs	Connecticut, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action Abemaciclib Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio CDK4/6 inhibitor Xentuzumab BI-836845 IGF-1/2 antagonist
NCT03030287	Ib	Platinum resistant ovarian cancer (inc expansion)	A Phase 1b Study of OMP-305B83 Plus Weekly Paclitaxel in Subjects With Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer	View Drugs	Colorado, Florida, North Carolina, Oklahoma, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action Navicixizumab anti-DLL4/VEGF bispecific monoclonal antibody OMP-305B83, OMP-305B83 DLL4 and VEGF antagonist Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02994953	Ib	Advanced solid tumors	A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors	View Drugs	Connecticut, Maryland, Missouri
Drug(s) in Trial Other Drug Names Main Known Action Avelumab MSB0010718C, Anti-PD-L1, Anti programmed death ligand 1 monoclonal antibody, Bavencio Blocks PD-L1 inhibition of T cells NHS-IL12 M9241, immunocytokine NHS-IL12 IL-12 receptor agonist
NCT03292172	Ib	Recurrent advanced ovarian cancer (inc expansion)	Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer	View Drugs	California, Massachusetts, Oklahoma, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells RO6870810 TEN-010, RG6146, BET inhibitor RO6870810 BET inhibitor
NCT03206177	Ib	Newly diagnosed, persistent, or recurrent ovarian carcinosarcoma	Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary	View Drugs	Oklahoma
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Galunisertib LY2157299 TGFBR1 antagonist Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT03236935	Ib	Advanced solid tumors with high MSI or dMMR	Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair Deficient Cancer	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action L-NMMA pan-nitric oxide synthase inhibitor, NG-monomethyl-L-arginine NOS inhibitor Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT03113188	Ib	Advanced solid tumors (inc expansion)	Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors	View Drugs	Arizona, Louisiana, Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action CBP501 G2 checkpoint inhibitor CBP501 G2 checkpoint inhibitor Cisplatin CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin DNA damaging agent Nivolumab Anti-PD-1 human mab MDX-1106, MDX-1106, ONO-4538, Opdivo, BMS-936558 Blocks PD-L1/2 inhibition of T cells
NCT03150810	Ib	Advanced solid tumors (inc ovarian expansion)	A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors	View Drugs	Michigan, Missouri, New York, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action BGB-290 PARP inhibitor BGB-290 PARP inhibitor Temozolomide Temodal, Temodar, Methazolastone DNA damaging agent
NCT03239145	Ib	Advanced solid tumors (inc ovarian expansion)	Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells Trebananib AMG 386 Angiopoietin 1/2 antagonist
NCT03162562	Ib	Recurrent or persistent ovarian cancer	Prospective Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of Oregovomab and Hiltonol® as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Advanced Epithelial Cancer of Ovarian, Tubal, or Peritoneal Origin	View Drugs	Florida, Virginia
Drug(s) in Trial Other Drug Names Main Known Action Oregovomab B43.13, Monoclonal Antibody B43.13, OvaRex Immune response against cancer expressing CA125 poly ICLC poly I:poly C with poly-1-lysine stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Hiltonol, poly-ICLC Activates dendritic cells and induces interferon production
NCT03601897	Ib	Advanced solid tumors	An Open-Label, Multicenter, Phase 1b Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Rebastinib multitargeted tyrosine kinase inhibitor DCC-2036 Multi-targeted kinase inhibitor
NCT03621982	Ib	Advanced solid tumors (inc expansion)	A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid Tumors	View Drugs	New York
Drug(s) in Trial Other Drug Names Main Known Action Camidanlumab Tesirine anti-CD25-PBD antibody-drug conjugate ADCT-301, ADCT-301 DNA damaging agent
NCT03611868	Ib	Advanced solid tumors	A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action APG-115 p53-HDM2 protein-protein interaction inhibitor APG-115, MDM2-p53 inhibitor APG-115 MDM2 inhibitor Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT03589651	Ib	Advanced solid tumors (inc expansion)	A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors	View Drugs	California, Illinois, North Carolina, Pennsylvania, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action Epacadostat IDO1 Inhibitor INCB024360, INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, 3-dioxygenase Inhibitor INCB024360 Inhibits IDO to stimulate immune response INCB050465 PI3K-delta inhibitor INCB050465 PI3K delta inhibitor INCMGA00012 anti-PD-1 monoclonal antibody MGA012 Blocks PD-L1 inhibition of T cells
NCT03586661	Ib	Platinum resistant or refractory ovarian cancer with BRCA1/2 mutations (except high grade serous)(inc expansion)	A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Copanlisib BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 pan-PI3K inhibitor Niraparib MK4827 PARP inhibitor
NCT03558139	Ib	Advanced solid tumors (inc ovarian expansion)	A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint Inhibitor Naïve Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy	View Drugs	Illinois, Michigan, Oklahoma, Texas
Drug(s) in Trial Other Drug Names Main Known Action Avelumab MSB0010718C, Anti-PD-L1, Anti programmed death ligand 1 monoclonal antibody, Bavencio Blocks PD-L1 inhibition of T cells Hu5F9-G4 anti-CD47 monoclonal antibody Hu5F9-G4 Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis
NCT03209401	Ia/Ib	Advanced solid tumors with mutations in ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1/2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC (inc expansion)	Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies	View Drugs	District of Columbia
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Niraparib MK4827 PARP inhibitor
NCT02718911	Ia/Ib	Advanced solid tumors (inc expansion)	A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors	View Drugs	Colorado, Florida, Georgia, New York, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action Durvalumab MEDI4736, Anti-B7H1 Monoclonal Antibody MEDI4736, Imfinzi Blocks PD-L1 inhibition of T cells LY3022855 IMC-CS4, anti-CSF-1R monoclonal antibody IMC-CS4 CSF1R antagonist and tumor-associated macrophage inhibitor Tremelimumab anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab Blocks CTLA-4 inhibition of T cells
NCT03295942	Ia	Advanced solid tumors	A Phase 1a Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of OMP-336B11 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action OMP-336B11 trimeric GITRL-Fc OMP-336B11 GITR (glucocorticoid-induced TNFR) agonist
NCT03519178	I/IIa	Platinum resistant ovarian cancer	Phase 1/2a Dose Escalation And Expansion Study Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamics And Anti-tumor Activity Of Pf-06873600 As A Single Agent And In Combination With Endocrine Therapy	View Drugs	California, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action PF-06873600